Human Immunoglobulin G specific for Cavia porcellus allergen 1–6 epitopes (IgG anti-Cav p 1–6)

Human IgG antibodies specific for Cav p 1–6 epitopes are a population of immunoglobulins produced by the human immune system that recognize the primary allergens of the domestic guinea pig (Cavia porcellus) [1]. These allergens, predominantly lipocalins (Cav p 1, 2, 3, 6) and serum albumin (Cav p 4), are responsible for inducing allergic sensitization and respiratory symptoms in exposed individuals [2]. In the context of clinical immunology and allergen-specific immunotherapy (AIT), these IgG antibodies—particularly the IgG4 subclass—serve as 'blocking antibodies' [3]. They function by competitively binding to allergen epitopes, thereby preventing the allergen from cross-linking IgE on the surface of mast cells and basophils, which would otherwise trigger the release of inflammatory mediators [4]. Consequently, the induction and measurement of these specific IgG antibodies are critical for monitoring the efficacy of desensitization treatments and the establishment of immunological tolerance [5]. Sources: [1] WHO/IUIS Allergen Nomenclature Database; [2] PMID: 15985001; [3] PMID: 24985403; [4] PMID: 11398089; [5] PMID: 21651587.

Other names

Guinea pig allergen-specific IgGAnti-Cav p 1-6 IgGBlocking antibodies for guinea pig allergensHuman IgG anti-Cav p

Induction of allergen-specific IgG (especially the IgG4 subclass) through allergen-specific immunotherapy (AIT) to act as a competitive inhibitor (blocking antibody) against allergen-specific IgE, thereby preventing the cross-linking of IgE on mast cells and basophils and inhibiting the release of inflammatory mediators.